Sign in

    Xuyang Li

    Vice President and Equity Research Analyst at Jefferies

    Xuyang Li is a Vice President and Equity Research Analyst at Jefferies, specializing in the China Education and Consumer sector. He covers prominent companies such as New Oriental Education & Technology, TAL Education Group, and China Maple Leaf Education, delivering in-depth research and actionable investment insights. Since joining Jefferies in 2018, Li has been recognized for his strong sector expertise and thorough analytical work, building on prior experience as an equity research analyst at BOCOM International. He holds FINRA Series 7 and 63 licenses and has earned recognition for his rigorous research approach and valuable stock recommendations in his coverage universe.

    Xuyang Li's questions to Hyperfine (HYPR) leadership

    Xuyang Li's questions to Hyperfine (HYPR) leadership • Q4 2024

    Question

    Asked for a potential split of the first-half revenue guidance between Q1 and Q2, and inquired about the experience level and ramp-up expectations for the newly hired sales representatives.

    Answer

    The company declined to provide a quarterly breakdown of the first-half guidance, reiterating that growth is heavily weighted to the second half due to various catalysts. Regarding the sales team, they confirmed that underperforming reps were replaced at the end of 2024. The new hires have relevant experience in building new markets, have undergone a rigorous training program, and the company is confident they will be ready to execute when the new product upgrades are launched.

    Ask Fintool Equity Research AI

    Xuyang Li's questions to Hyperfine (HYPR) leadership • Q4 2024

    Question

    Xuyang Li of Jefferies requested color on the potential split between Q1 and Q2 revenue within the $6 million first-half 2025 guidance. He also asked about the experience level of the recently hired sales representatives and the company's confidence in their ability to ramp up effectively for the second half of the year.

    Answer

    CFO Brett Hale and Executive Maria Sainz declined to provide a quarterly breakdown for the first half, reiterating that they expect significant growth acceleration in the second half driven by multiple catalysts. Regarding the sales team, Sainz explained that underperforming reps were replaced to prepare for new technology launches. She detailed that the new hires have experience in building new markets and the brain space, have undergone a rigorous training program, and she expressed high confidence in their readiness to execute when the new product upgrades are released.

    Ask Fintool Equity Research AI

    Xuyang Li's questions to SI-BONE (SIBN) leadership

    Xuyang Li's questions to SI-BONE (SIBN) leadership • Q3 2024

    Question

    Xuyang Li of Jefferies asked for a high-level assessment of the SI joint fusion market's health and competitive dynamics. He also questioned the drivers of sales representative productivity, the path to exceeding $2 million per territory, and the rationale for increasing rep hiring.

    Answer

    CEO Laura Francis affirmed SI-BONE's position as the market leader, citing a comprehensive product portfolio and strong educational approach. CFO Anshul Maheshwari added that over 60% of new active physicians perform multiple procedure types. Regarding sales productivity, Francis credited the hybrid model of direct reps and agents, while Maheshwari noted top territories reach $4 million and the company plans to expand to 100 territories over 18-24 months to support its growing platform.

    Ask Fintool Equity Research AI

    Xuyang Li's questions to Bausch & Lomb (BLCO) leadership

    Xuyang Li's questions to Bausch & Lomb (BLCO) leadership • Q3 2024

    Question

    Xuyang Li inquired about the sustainability of growth in the dry eye portfolio, including the halo effect on OTC products, and asked about the health of the U.S. consumer and dynamics in the contact lens market.

    Answer

    CEO Brenton L. Saunders highlighted the comprehensive dry eye strategy, noting a large untapped market for both prescription (Miebo, Xiidra) and OTC products (Blink, Artelac), suggesting a long runway for growth. For contact lenses, he pointed to sustained momentum from the global rollout of the full Daily SiHy portfolio. Regarding the consumer market, he acknowledged retailer destocking but emphasized that underlying consumption data remains very strong.

    Ask Fintool Equity Research AI